undamentalytics Newsletter
Sign in

XTL Biopharmaceuticals LTD key statistics and ratios

In fiscal 2024, XTL Biopharmaceuticals LTD had return on equity of -18.9%, an operating margin of -171.8%, debt equal to 2.5% of equity and a current ratio of 0.61. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 2024
Gross margin0.7%
Operating margin−171.8%
Net margin−227.7%
Free-cash-flow margin−370.7%
Return on equity−18.9%
Return on assets−12.0%
Asset turnover0.05
Current ratio0.61
Debt to equity2.5%
Interest cover (operating income ÷ interest)n/m
R&D as % of revenue3.5%
Capital spending as % of revenue12.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 1 checks passed · December 31, 2025
  • Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$2m against $7,000 of interest.

From XTL Biopharmaceuticals LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from XTL Biopharmaceuticals LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to XTL Biopharmaceuticals LTD.